EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer

Amir Karimzadeh, Kimberley Hansen, Ergela Hasa, Bernhard Haller, Matthias M Heck, Robert Tauber, Calogero D Alessandria, Wolfgang A Weber, Matthias Eiber, Isabel Rauscher

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-07003-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Amir Karimzadeh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany. amir.karimzadeh@uke.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Glutamate Carboxypeptidase II, Positron-Emission Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This retrospective analysis evaluates baseline 18 F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [ 177 Lu]Lu-PSMA-I&T.

Methods

A total of 188 mCRPC patients with baseline 18 F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics. Outcome measures included prostate-specific antigen (PSA) response, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Univariate and multivariate regression analyses assessed the impact of baseline imaging and pretherapeutic clinical parameters on outcome. Event time distributions were estimated with the Kaplan-Meier method, and groups were compared with log-rank tests.

Results

Significant prognostic parameters for PSA response and PSA-PFS included log-transformed whole-body SUVmax (odds ratio (OR), 3.26, 95% confidence interval (CI), 2.01–5.55 and hazard ratio (HR), 0.51, 95% CI, 0.4–0.66; both p < 0.001) and prior chemotherapy (OR 0.3, 95% CI, 0.12–0.72 and HR 1.64, 95% CI, 1.07–2.58; p = 0.008 and p = 0.028, respectively). For OS, significant prognosticators were the following log-transformed parameters: number of lesions (HR 1.38, 95% CI, 1.24–1.53; p < 0.001), TTV (HR 1.27, 95% CI, 1.18–1.37; p < 0.001), and ITLV (HR 1.24, 95% CI, 1.16–1.33; p < 0.001), with log-transformed TTV (HR 1.15, 95% CI, 1.04–1.27; p = 0.008) remaining significant in multivariate analysis.

Conclusion

At baseline, SUV-based 18 F-flotufolastat PET metrics (e.g., whole-body SUVmax) serve as significant positive prognosticators for short-term outcomes (PSA response and PSA-PFS). In contrast, volume-based metrics (e.g., TTV) are significant negative prognosticators for long-term outcome (OS), in mCRPC patients treated with [ 177 Lu]Lu-PSMA-I&T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumGlutamate Carboxypeptidase IIPositron-Emission TomographyAntigens, SurfaceHumansMaleAgedMiddle AgedRetrospective StudiesNeoplasm MetastasisAged, 80 and overRadioisotopesTreatment OutcomePrognosisRadiopharmaceuticals

Stichwörter der Autor:innen

18F-flotufolastatPSMARadioligand therapy[177Lu]Lu-PSMA-I&TmCRPC

Substanzen

LutetiumGlutamate Carboxypeptidase IILutetium-177FOLH1 protein, humanRadioisotopesAntigens, SurfaceRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany. amir.karimzadeh@uke.de.
  • Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. amir.karimzadeh@uke.de.
  • Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
  • Institute of AI and Informatics in Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
  • Department of Urology, School of Medicine, Technical University of Munich, Munich, Germany.
  • Bavarian Cancer Research Center, Munich, Germany.

Förderung

  • Technische Universität München

Zitieren

APA

Karimzadeh, A., Hansen, K., Hasa, E., Haller, B., Heck, M. M., Tauber, R., D Alessandria, C., Weber, W. A., Eiber, M., & Rauscher, I. (2025). Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07003-2

Vancouver

Karimzadeh A, Hansen K, Hasa E, Haller B, Heck MM, Tauber R, et al. Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-07003-2

BibTeX
@article{Karimzadeh2025,
  author = {Karimzadeh, Amir and Hansen, Kimberley and Hasa, Ergela and Haller, Bernhard and Heck, Matthias M and Tauber, Robert and D Alessandria, Calogero and Weber, Wolfgang A and Eiber, Matthias and Rauscher, Isabel},
  title = {Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-07003-2}
}
Kostenlos starten →